These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38104352)

  • 41. Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.
    Zhou MY; Bui NQ; Charville GW; Ganjoo KN; Pan M
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment.
    Vanni S; Miserocchi G; Gallo G; Fausti V; Gabellone S; Liverani C; Spadazzi C; Cocchi C; Calabrese C; De Luca G; Bassi M; Gessaroli M; Tomasetti N; Campobassi A; Pieri F; Ercolani G; Cavaliere D; Gurrieri L; Riva N; Recine F; Ibrahim T; Mercatali L; Jones R; De Vita A
    Exp Hematol Oncol; 2024 Aug; 13(1):74. PubMed ID: 39103896
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Iwata S; Sugaya J; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2022 May; 35(3):936-943. PubMed ID: 35292923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.
    Hwang JA; Yang HM; Hong DP; Joo SY; Choi YL; Park JH; Lazar AJ; Pollock RE; Lev D; Kim SJ
    Oncotarget; 2014 Oct; 5(19):9065-78. PubMed ID: 25238053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel HMGA2::KITLG fusion in a dedifferentiated liposarcoma with amplification of MDM2 and HMGA2.
    Zhou S; Zhang C; Zhang Z; Hu Y; Zhao L; Hu W; Chen S; Li B; Xiao S
    Genes Chromosomes Cancer; 2024 Jan; 63(1):e23200. PubMed ID: 37698344
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Casadei L; Calore F; Braggio DA; Zewdu A; Deshmukh AA; Fadda P; Lopez G; Wabitsch M; Song C; Leight JL; Grignol VP; Lev D; Croce CM; Pollock RE
    Cancer Res; 2019 Oct; 79(19):4911-4922. PubMed ID: 31387924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas.
    Laroche A; Chaire V; Algeo MP; Karanian M; Fourneaux B; Italiano A
    Oncotarget; 2017 Aug; 8(33):53968-53977. PubMed ID: 28903316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.
    Horvai AE; DeVries S; Roy R; O'Donnell RJ; Waldman F
    Mod Pathol; 2009 Nov; 22(11):1477-88. PubMed ID: 19734852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liposarcoma of the pleural cavity.
    Kawai T; Nakashima H; Washimi K; Yokose T; Matsuo T; Nakayama M; Shinohara N; Kuroda H; Ishida K; Akiba J; Ishikawa M; Urabe S; Shiraishi J; Shiraishi T; Sakamoto A; Matsukuma S
    Hum Pathol; 2023 Jun; 136():105-113. PubMed ID: 37023867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.
    Pilotti S; Della Torre G; Lavarino C; Sozzi G; Minoletti F; Vergani B; Azzarelli A; Rilke F; Pierotti MA
    J Pathol; 1998 Jun; 185(2):188-90. PubMed ID: 9713346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
    Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
    Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
    Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
    Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Paratesticular liposarcoma: the clinicopathological features of nineteen cases].
    Yang SM; Wu RC; Qi SS; You JF
    Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):17-22. PubMed ID: 34979748
    [No Abstract]   [Full Text] [Related]  

  • 54. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.
    Thirasastr P; Somaiah N
    Ther Adv Med Oncol; 2022; 14():17588359221081073. PubMed ID: 35251319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Establishment and characterization of a novel patient-derived cell line of dedifferentiated liposarcoma, NCC-DDLPS6-C1.
    Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Akiyama T; Nakagawa R; Kamio S; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2022 Jul; 35(4):1270-1278. PubMed ID: 35604485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.
    Traweek RS; Cope BM; Roland CL; Keung EZ; Nassif EF; Erstad DJ
    Front Oncol; 2022; 12():1006959. PubMed ID: 36439412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Whole exome sequencing of well-differentiated liposarcoma and dedifferentiated liposarcoma in older woman: a case report.
    Zhao Z; Chen X; Xu J; Shi Y; Mak TK; Huo M; Zhang C
    Front Med (Lausanne); 2023; 10():1237246. PubMed ID: 37649981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histological Classification and Immunohistochemical Evaluation of MDM2 and CDK4 Expression in Canine Liposarcoma.
    Avallone G; Roccabianca P; Crippa L; Lepri E; Brunetti B; Bernardini C; Forni M; Olandese A; Sarli G
    Vet Pathol; 2016 Jul; 53(4):773-80. PubMed ID: 26993784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic Value of MDM2 and DDIT3 Fluorescence In Situ Hybridization in Liposarcoma Classification: A Single-Institution Experience.
    Cho J; Lee SE; Choi YL
    Korean J Pathol; 2012 Apr; 46(2):115-22. PubMed ID: 23109990
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status.
    Makise N; Sekimizu M; Kubo T; Wakai S; Hiraoka N; Komiyama M; Fukayama M; Kawai A; Ichikawa H; Yoshida A
    Am J Surg Pathol; 2018 May; 42(5):656-664. PubMed ID: 29309298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.